1-5 of 5
Catherine Van Poznak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Kimberly N. Johnson, Richard G. Abramson, Sheau-Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2111–2123.
https://doi.org/10.1158/1078-0432.CCR-19-2170
Published: 01 May 2020
View articletitled, TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Open the PDF for TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases

Aki Morikawa, Elisa de Stanchina, Elena Pentsova, Margaret M. Kemeny, Bob T. Li, Kendrick Tang, Sujata Patil, Martin Fleisher, Catherine Van Poznak, Larry Norton, Andrew D. Seidman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3784–3792.
https://doi.org/10.1158/1078-0432.CCR-18-3502
Published: 01 July 2019
View articletitled, Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
Open the PDF for Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases in another window
Includes: Supplementary data
Journal Articles

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy

Daniel L. Hertz, Kelley M. Kidwell, Kiran Vangipuram, Feng Li, Manjunath P. Pai, Monika Burness, Jennifer J. Griggs, Anne F. Schott, Catherine Van Poznak, Daniel F. Hayes, Ellen M. Lavoie Smith, N. Lynn Henry
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3602–3610.
https://doi.org/10.1158/1078-0432.CCR-18-0656
Published: 31 July 2018
View articletitled, Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy
Open the PDF for Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy in another window
Includes: Supplementary data
Journal Articles

TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis

Zahi Mitri, Rita Nanda, Kimberly Blackwell, Colleen M. Costelloe, Ilona Hood, Caimiao Wei, Abenaa M. Brewster, Nuhad K. Ibrahim, Kimberly B. Koenig, Gabriel N. Hortobagyi, Catherine Van Poznak, Mothaffar F. Rimawi, Stacy Moulder-Thompson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5706–5712.
https://doi.org/10.1158/1078-0432.CCR-15-2845
Published: 30 November 2016
View articletitled, TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Open the PDF for TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis in another window
Journal Articles

Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer

Monica N. Fornier, Andrew D. Seidman, Diana Lake, Gabriella D'Andrea, Jacqueline Bromberg, Mark Robson, Catherine Van Poznak, Katherine S. Panageas, Marietta Atienza, Larry Norton, Clifford Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (1): 223–227.
https://doi.org/10.1158/1078-0432.CCR-06-1731
Published: 02 January 2007
View articletitled, Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer
Open the PDF for Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer in another window